Discovery of MK-4409, a Novel Oxazole FAAH Inhibitor for the Treatment of Inflammatory and Neuropathic Pain.

No abstract is available for this paper.

• Publication year

  2014

• Venue

  ACS Medicinal Chemistry Letters

• Publication date

  2014-06-12

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1021/ml5001239PMID 24944750PMCID PMC4060928
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Discovery of MK-3168: A PET Tracer for Imaging Brain Fatty Acid Amide Hydrolase.

  2013cited by this paper
• Discovery of PF-04457845: A Highly Potent, Orally Bioavailable, and Selective Urea FAAH Inhibitor.

  2011cited by this paper
• Identification of potent, noncovalent fatty acid amide hydrolase (FAAH) inhibitors.

  2011cited by this paper
• Recent Advances Toward Pain Therapeutics

  2011cited by this paper
• Synthesis and evaluation of benzothiazole-based analogues as novel, potent, and selective fatty acid amide hydrolase inhibitors.

  2009cited by this paper
• The endocannabinoid system as a target for novel anxiolytic and antidepressant drugs.

  2009cited by this paper
• Analogs of MK-499 are differentially affected by a mutation in the S6 domain of the hERG K+ channel.

  2009cited by this paper
• Structure-guided inhibitor design for human FAAH by interspecies active site conversion

  2008cited by this paper
• Suzuki coupling of oxazoles.

  2006cited by this paper
• Discovery of a potent, selective, and efficacious class of reversible alpha-ketoheterocycle inhibitors of fatty acid amide hydrolase effective as analgesics.

  2005cited by this paper
• Correction for Gobbi et al., Antidepressant-like activity and modulation of brain monoaminergic transmission by blockade of anandamide hydrolysis

  2005cited by this paper
• Reversible Inhibitors of Fatty Acid Amide Hydrolase That Promote Analgesia: Evidence for an Unprecedented Combination of Potency and Selectivity

  2004cited by this paper
• Cyclohexylcarbamic acid 3'- or 4'-substituted biphenyl-3-yl esters as fatty acid amide hydrolase inhibitors: synthesis, quantitative structure-activity relationships, and molecular modeling studies.

  2004cited by this paper
• Mice lacking fatty acid amide hydrolase exhibit a cannabinoid receptor‐mediated phenotypic hypoalgesia

  2004cited by this paper
• Sonogashira coupling of functionalized trifloyl oxazoles and thiazoles with terminal alkynes: synthesis of disubstituted heterocycles.

  2002cited by this paper
• Supersensitivity to anandamide and enhanced endogenous cannabinoid signaling in mice lacking fatty acid amide hydrolase

  2001cited by this paper
• Distinct Domains of the CB1 Cannabinoid Receptor Mediate Desensitization and Internalization

  1999cited by this paper
• Molecular characterization of human and mouse fatty acid amide hydrolases.

  1997cited by this paper
• Structure Determination of an Endogenous Sleep-Inducing Lipid, cis-9-Octadecenamide (Oleamide): A Synthetic Approach to the Chemical Analysis of Trace Quantities of a Natural Product

  1996cited by this paper
• An experimental model for peripheral neuropathy produced by segmental spinal nerve ligation in the rat

  1992cited by this paper
• Evidence that adjuvant arthritis in the rat is associated with chronic pain

  1987cited by this paper

• Current Nonopioid Small Molecule Approaches Toward the Treatment of Neuropathic Pain.

  2025cites this paper
• Anandamide and the urinary bladder

  2024cites this paper
• Regiodivergent Synthesis of 4- and 5-Sulfenyl Oxazoles from Alkynyl Thioethers.

  2024cites this paper
• Synthesis of Oxazoles Containing CF3-Substituted Alcohol Unit via Tandem Cycloisomerization/Hydroxyalkylation from N-Propargylamides with Trifluoropyruvates

  2024cites this paper
• Pharmacological Inventions for Alzheimer Treatment in the United States of America: A Revision Patent from 2010–2020

  2023cites this paper
• Review on Chemistry of Oxazole derivatives: Current to Future Therapeutic Prospective

  2023cites this paper
• Evaluation of dual potentiality of 2,4,5-trisubstituted oxazole derivatives as aquaporin-4 inhibitors and anti-inflammatory agents in lung cells

  2023cites this paper
• Quantum Chemical Exploration of the Mechanism of Robinson–Gabriel Reaction

  2023cites this paper
• The Amoebicidal Activity of Diferrocenyl Derivatives: A Significant Dependence on the Electronic Environment

  2023cites this paper
• Lead optimization study on indoline-2,3-dione derivatives as potential fatty acid amide hydrolase inhibitors

  2022cites this paper
• Oxazole and isoxazole: From one-pot synthesis to medical applications

  2022cites this paper
• The role of endocannabinoid pathway in the neuropathology of Alzheimer's disease: Can the inhibitors of MAGL and FAAH prove to be potential therapeutic targets against the cognitive impairment associated with Alzheimer's disease?

  2021cites this paper
• Safety, Tolerability, and Pharmacokinetics of FAAH Inhibitor BIA 10‐2474: A Double‐Blind, Randomized, Placebo‐Controlled Study in Healthy Volunteers

  2021cites this paper
• Targeting Endocannabinoid Metabolism: an Arrow with Multiple Tips Against Multiple Sclerosis

  2020cites this paper
• Ullmann‐Ma Reaction: Development, Scope and Applications in Organic Synthesis †

  2020cites this paper
• Pharmacological characterization of a novel, potent, selective, and orally active fatty acid amide hydrolase inhibitor, PKM‐833 [(R)‐N‐(pyridazin‐3‐yl)‐4‐(7‐(trifluoromethyl)chroman‐4‐yl)piperazine‐1‐carboxamide] in rats: Potential for the treatment of inflammatory pain

  2020cites this paper
• Discovery and evaluation of novel FAAH inhibitors in neuropathic pain model.

  2019cites this paper
• Hydrogen bonded complexes of oxazole family: electronic structure, stability, and reactivity aspects

  2018cites this paper
• Enhanced endocannabinoid tone as a potential target of pharmacotherapy

  2018cites this paper
• Recent advance in oxazole-based medicinal chemistry.

  2018cites this paper
• Discovery of a Potent, Long‐Acting, and CNS‐Active Inhibitor (BIA 10‐2474) of Fatty Acid Amide Hydrolase

  2018cites this paper
• Therapeutic Potential of Fatty Acid Amide Hydrolase, Monoacylglycerol Lipase, and N-Acylethanolamine Acid Amidase Inhibitors.

  2017cites this paper
• Metabolism of N-Acylethanolamines: To Phase II and Back Again

  2017cites this paper
• A patent review of Monoacylglycerol Lipase (MAGL) inhibitors (2013-2017)

  2017cites this paper
• Synthesis of fluorescent trisubstituted oxazoles via a facile tandem Staudinger/aza-Wittig/isomerization reaction

  2017cites this paper
• Beyond the Direct Activation of Cannabinoid Receptors: New Strategies to Modulate the Endocannabinoid System in CNS-Related Diseases.

  2016cites this paper
• A series of 2, 4, 5-trisubstituted oxazole: Synthesis, characterization and DFT modelling

  2016cites this paper
• Palladium‐Catalyzed C–S Bond Formation of Stable Enamines with Arene/Alkanethiols: Highly Regioselective Synthesis of β‐Amino Sulfides

  2016cites this paper
• Targeting the Endocannabinoid System in Psychiatric Illness

  2016cites this paper
• Gram Scale Syntheses of (-)-Incarvillateine and Its Analogs. Discovery of Potent Analgesics for Neuropathic Pain.

  2016cites this paper
• A rapid route for the preparation of pyrimido[5,4-d]- and pyrido[3,2-d]oxazoles

  2015cites this paper
• Fatty acid amide hydrolase inhibitors: a patent review (2009 – 2014)

  2015cites this paper
• The Potential of Inhibitors of Endocannabinoid Metabolism for Drug Development: A Critical Review.

  2015cites this paper